ArticleBMC public health2024
Tracking the epidemiological trends of female breast cancer in Saudi Arabia since 1990 and forecasting future statistics using global burden of disease data, time-series analysis.
Article in BMC public health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Article
- Improving Breast Cancer Screening Coverage in Primary Healthcare: A Quality-Improvement Study (2023-2025).Cureus · 2026Article
- Physicochemical Determinants of Bioactivity in Acacia Gum-Derived Silver Nanoparticles: Enhanced Selective Toxicity Toward MCF-7 Breast Cancer Cells.International journal of molecular sciences · 2026Article
- Hybrid tuned deep learning model for breast cancer diagnosis using genetic data.Scientific reports · 2026Article
- Beyond mammography: Superior performance of ultrasound in early-onset breast cancer implications for age-specific, density-tailored screening.Turkish journal of surgery · 2026Article
- Prognostic Significance of Lymphovascular Invasion in Breast Cancer: Insights From a Retrospective Analysis at a Tertiary Care Center.Saudi medical journal · 2026Article
- Perceived Stress and Sociodemographic Factors Among Saudi Women with Breast Cancer: A Cross-Sectional Study.Journal of clinical medicine · 2026Article
- Temporal trends and decomposition analysis of cardiovascular disease burden in China and worldwide from 1990 to 2021, with projections to 2036.Archives of medical science : AMS · 2026Article
- Management of HER2+ Breast Cancer with and without Brain Metastases in Saudi Arabia: Literature Insights and an Expert Survey of Current Practices.Breast cancer (Dove Medical Press) · 2026Article
- Perceptions of Breast Cancer: A Cross-Sectional Study Using the Breast Cancer Perception Scale (BPS).Breast cancer : basic and clinical research · 2026Article
- Genomic and epigenomic diversity of breast cancer across Western and MENA populations: implications for precision oncology.Frontiers in oncology · 2026Review
- Therapeutic potential of selenium in breast cancer: targeting apoptosis and proliferation pathways.Annals of medicine and surgery (2012) · 2026Review
- Modulating N1 and N2 neutrophils in breast cancer: potential therapeutic approaches - a narrative review.Annals of medicine and surgery (2012) · 2026Review
- The global burden of aortic aneurysm attributable to smoking from 1990 to 2021: Current trends and projections for 2036.Tobacco induced diseases · 2026Article
- Voxel-wise analysis of brain metastasis predilection sites in breast cancer by clinical features.Discover oncology · 2025Article
- Gender differences in the burden of near vision loss in China: An analysis based on GBD 2021 data.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2025Article
- Long-Term Trends and Projections of Multiple Myeloma Across Three Continents: A Comparative Study of China, the United States of America, the Russian Federation, England and France (1990-2036).Cancer medicine · 2025Article
- Global, regional, and national trends in the burden of melanoma and non-melanoma skin cancer: insights from the global burden of disease study 1990-2021.Scientific reports · 2025Article
- Comprehensive analysis of the global, regional, and national burden of benign prostatic hyperplasia from 1990 to 2021.Scientific reports · 2025Article
- Synthesis and Anticancer Evaluation ofInternational journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFemale breast cancer stands as the prime type of cancer in the Kingdom of Saudi Arabia (KSA), with a high incidence and mortality rates. This study assessed the burden of female breast cancer in KSA by analyzing and forecasting its incidence, mortality, and disability-adjusted life years (DALYs).
methodsWe retrieved data from the Global Burden of Disease (GBD) about female breast cancer from 1990 to 2021. Time-series analysis used the autoregressive integrated moving average (ARIMA) model to forecast female breast cancer statistics from 2022 to 2026.
resultsFrom 1990 to 2021, KSA reported 77,513 cases of female breast cancer. The age groups with the highest number of cases are 45-49 years, followed by 40-44 years, 50-54 years, and 35-39 years. The analysis also showed fewer cases in the younger age groups, with the lowest number in the less than 20-year-old age group. From 1990 to 2021, KSA reported 19,440 deaths due to breast cancer, increasing from 201 cases in 1990 to 1,190 cases in 2021. The age-standardized incidence rate/100,000 of breast cancer increased from 15.4 (95% confidence interval (CI) 11.2-21.0) in 1990 to 46.0 (95%CI 34.5-61.5) in 2021. The forecasted incidence rate of female breast cancer will be 46.5 (95%CI 45.8-46.5) in 2022 and 49.6 (95%CI 46.8-52.3) in 2026. The age-standardized death rate per 100,000 Saudi women with breast cancer increased from 6.73 (95%CI 6.73-9.03) in 1990 to 9.77 (95%CI 7.63-13.00) in 2021. The forecasted female breast cancer death rate will slightly decrease to 9.67 (95%CI 9.49-9.84) in 2022 and to 9.26 (95%CI 8.37-10.15) in 2026. DALYs increased from 229.2 (95%CI 165.7-313.6) in 1990 to 346.1 (95%CI 253.9-467.2) in 2021. The forecasted DALYs of female breast cancer will slightly decrease to 343.3 (95%CI 337.2-349.5) in 2022 reaching 332.1 (95%CI 301.2-363.1) in 2026.
conclusionsFemale breast cancer is still a significant public health burden that challenges the health system in KSA, current policies and interventions should be fashioned to alleviate the disease morbidity and mortality and mitigate its future burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.